ASRT Assertio Holdings, Inc.

Nasdaq assertiotx.com


$ 0.89 $ 0.01 (1.61 %)    

Wednesday, 12-Nov-2025 12:20:21 EST
QQQ $ 619.38 $ -5.40 (-0.86 %)
DIA $ 483.35 $ 2.79 (0.58 %)
SPY $ 682.51 $ -2.28 (-0.33 %)
TLT $ 90.26 $ 0.31 (0.34 %)
GLD $ 385.85 $ 5.70 (1.5 %)
$ 0.9203
$ 0.87
$ 0.89 x 100
$ 0.90 x 1,000
$ 0.87 - $ 0.94
$ 0.51 - $ 1.08
4,496,070
na
88.58M
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-10-2025 09-30-2025 10-Q
2 08-11-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 03-12-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-06-2024 03-31-2024 10-Q
8 03-11-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-08-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 03-10-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 03-12-2021 12-31-2020 10-K
21 11-06-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 assertio-holdings-narrows-fy2025-sales-guidance-from-108000m-118000m-to-110000m-112000m-vs-111089m-est

Assertio Holdings (NASDAQ:ASRT) narrows FY2025 sales outlook from $108.000 million-$118.000 million to $110.000 million-$112.00...

 assertio-holdings-q3-adj-eps-018-beats-009-estimate-sales-49459m-beat-27020m-estimate

Assertio Holdings (NASDAQ:ASRT) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $(0...

 assertio-appoints-mark-l-reisenauer-as-ceo-effective-immediately-succeeding-brendan-p-ogrady

Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), today announced that its Board of Directo...

 assertio-presents-data-on-sympazan-showing-how-it-is-being-used-in-daily-clinical-practice-to-treat-patients-with-lennox-gastaut-syndrome

New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a sev...

 assertio-holdings-will-present-new-data-for-sympazan-clobazam-at-the-annual-meeting-of-the-american-neurological-association

Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive ...

 hc-wainwright--co-maintains-buy-on-assertio-holdings-lowers-price-target-to-3

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Assertio Holdings (NASDAQ:ASRT) with a Buy and lowers the price...

 assertio-holdings-narrows-fy2025-sales-guidance-from-10800m-12300m-to-10800m-11800m-vs-11372m-est

Assertio Holdings (NASDAQ:ASRT) narrows FY2025 sales outlook from $108.00 million-$123.00 million to $108.00 million-$118.00 mi...

 assertio-holdings-q2-adj-eps-002-beats-008-estimate-sales-2922m-beat-2786m-estimate

Assertio Holdings (NASDAQ:ASRT) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0...

 hc-wainwright--co-reiterates-buy-on-assertio-holdings-maintains-35-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Assertio Holdings (NASDAQ:ASRT) with a Buy and maintains $3.5 ...

 assertio-holdings-q1-adj-eps-004-beats-006-estimate-sales-2649m-miss-2752m-estimate

Assertio Holdings (NASDAQ:ASRT) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0...

 hc-wainwright--co-maintains-buy-on-assertio-holdings-lowers-price-target-to-35

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Assertio Holdings (NASDAQ:ASRT) with a Buy and lowers the price...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION